United States
Print page content Print
Increase text size Decrease text size
Text Size

In this section

Safety

PALLADIA adverse events can be serious, but most are mild to moderate and are generally manageable

  •    PALLADIA is a novel oral therapy that has been specifically developed for dogs3
  •    Studies demonstrate that 3.25 mg/kg EOD dosing maintains therapeutic plasma
              concentrations for a portion of the dosing period with clinical tolerability2,3
  •    PALLADIA has been studied in dogs, and its safety profile is well characterized2,3
    •     GI AEs are the most commonly observed
  •    Careful monitoring for GI AEs is recommended. Serious, and sometimes fatal,
              GI complications, including GI perforations, have occurred rarely in dogs treated1,3
              with PALLADIA
    •     Early recognition is critical

IMPORTANT SAFETY INFORMATION: During clinical studies, the most common adverse events associated with PALLADIA included: diarrhea, anorexia (including decreased appetite), lethargy, neutropenia, emesis, lameness, weight loss, musculoskeletal disorder, and blood in stool/GI bleed/hemorrhagic diarrhea. PALLADIA may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. Serious and sometime fatal GI complications, including GI perforation, have occurred rarely in dogs treated with PALLADIA. If GI ulceration is suspected stop drug administration and treat appropriately. Children should not come in contact with PALLADIA. In addition, all individuals, including children and pregnant women, should avoid direct contact with broken or partially dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. To report a suspected adverse reaction call Zoetis at 1-888-963-8471. See full Prescribing Information

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. August 2015. PAL-00040

REFERENCES:

1. Package Insert
2. London CA et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9:2755-68.
3. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009, 151(11):3856-3865.